0001179110-15-012442.txt : 20150820
0001179110-15-012442.hdr.sgml : 20150820
20150820190946
ACCESSION NUMBER: 0001179110-15-012442
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20150818
FILED AS OF DATE: 20150820
DATE AS OF CHANGE: 20150820
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ABIOMED INC
CENTRAL INDEX KEY: 0000815094
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042743260
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 22 CHERRY HILL DR
CITY: DANVERS
STATE: MA
ZIP: 01923
BUSINESS PHONE: 9787775410
MAIL ADDRESS:
STREET 1: 22 CHERRY HILL DRIVE
CITY: DANVERS
STATE: MA
ZIP: 01923
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MINOGUE MICHAEL R
CENTRAL INDEX KEY: 0001286370
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-09585
FILM NUMBER: 151067315
MAIL ADDRESS:
STREET 1: 22 CHERRY HILL DR
STREET 2: C/O ABIOMED INC
CITY: DANVERS
STATE: MA
ZIP: 01923
4
1
edgar.xml
FORM 4 -
X0306
4
2015-08-18
0
0000815094
ABIOMED INC
ABMD
0001286370
MINOGUE MICHAEL R
C/O ABIOMED, INC.,
22 CHERRY HILL DRIVE
DANVERS
MA
01923
1
1
0
0
President, CEO, Chairman
Common Stock $.01 par value
2015-08-18
4
M
0
146800
5.86
A
386518
D
Common Stock $.01 par value
2015-08-18
4
S
0
38126
105.0480
D
348392
D
Common Stock $.01 par value
2015-08-18
4
S
0
28530
105.9233
D
319862
D
Common Stock $.01 par value
2015-08-18
4
S
0
7214
106.7676
D
312648
D
Common Stock $.01 par value
2015-08-18
4
S
0
523
107.4812
D
312125
D
Common Stock $.01 par value
2015-08-19
4
S
0
13996
102.9076
D
298129
D
Common Stock $.01 par value
2015-08-19
4
S
0
21601
103.7841
D
276528
D
Common Stock $.01 par value
2015-08-19
4
S
0
31210
104.7292
D
245318
D
Common Stock $.01 par value
2015-08-19
4
S
0
5600
105.5014
D
239718
D
Common Stock $.01 par value
36082
I
By Trust
Stock Option (right to buy)
13.57
2007-06-01
2016-06-01
Common Stock
0
82000
D
Stock Option (right to buy)
13.80
2009-05-23
2018-05-23
Common Stock
0
28333
D
Stock Option (right to buy)
18.63
2009-06-15
2018-08-13
Common Stock
0
76875
D
Stock Option (right to buy)
5.86
2015-08-18
4
M
0
146800
0
D
2010-05-28
2019-05-28
Common Stock
0
0
D
Stock Option (right to buy)
5.86
2010-05-28
2019-05-28
Common Stock
0
56700
D
Stock Option (right to buy)
10.03
2011-06-03
2020-06-03
Common Stock
0
105000
D
Stock Option (Right to Buy)
22.44
2013-05-22
2022-05-22
Common Stock
0
50000
D
Stock Option (Right to Buy)
23.15
2014-05-14
2024-05-14
Common stock
0
21250
D
Stock Option (right to buy)
21.55
2015-05-14
2024-05-14
Common Stock
0
85000
D
Stock Option (right to buy)
66.25
2016-05-13
2025-05-13
Common Stock
0
35000
D
Sale of common stock pursuant to reporting owner's 10b5-1 plan.
These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
These options become exercisable based on the achievement of certain performance milestones.
These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
Grant to reporting person of option to buy shares of Common Stock under the ABIOMED, Inc. 2000 Stock Incentive Plan.
This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $104.4100 and $105.4000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $105.4100 and $106.4000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $106.4100 and $107.4000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $107.4800 and $107.5150. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $102.3000 and $103.2750. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $103.3100 and $104.3000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $104.3100 and $105.3000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $105.3100 and $105.9000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
These securities are held by the Renee D. Minogue Revocable Trust, Renee D. Minogue, trustee DTD 12/29/2005.
/s/ Stephen C. McEvoy (by power of attorney)
2015-08-20
EX-24
2
ex24minogue.txt
LIMITED POWER OF ATTORNEY
The undersigned does hereby appoint each of
Stephen McEvoy, Ian McLeod and Loretta Wedge, signing singly,
the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the
undersigned, in the undersigned's capacity as a
director or officer of ABIOMED, Inc. (the "Company"),
Forms 3, 4 and 5 in accordance with Section 16(a) of
the Securities Exchange Act of 1934 and the rules
thereunder;
(2) do and perform any and all acts for and on
behalf of the undersigned which may be necessary or
desirable to complete and execute any such Form 3, 4
or 5 and timely file such form with the United States
Securities and Exchange Commission and any stock
exchange or similar authority; and
(3) take any other action of any type whatsoever
in connection with the foregoing which, in the opinion
of such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the
undersigned, it being understood that the documents
executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall
be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.
The undersigned hereby grants to each such
attorney-in-fact full power and authority to do and
perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the
exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the
undersigned might or could do if personally present,
with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-
fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and
powers herein granted. The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are
not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section
16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required
to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in
securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, this power of attorney has
been executed as of the 2nd day of October, 2008 and
shall remain in full force and effect until withdrawn
by the undersigned in writing.
Signature: /s/ Michael R. Minogue
Print Name: Michael R. Minogue